

Reason: Failed to furnish a valid surety bond.

License Number: 3247.

Name: Drew Freight, Inc.

Address: 29 Broadway, New York, NY 10006-3030.

Date Revoked: November 20, 1991.

Reason: Failed to furnish a valid surety bond.

License Number: 1958.

Name: Wilson Maritime, Inc.

Address: 125 Elizabeth St., #3B, New York, NY 10013.

Date Revoked: November 22, 1991.

Reason: Failed to furnish a valid surety bond.

License Number: 2008R.

Name: Moses E. Shamash & Company.

Address: 5758 W. Century Blvd., suite 212, Los Angeles, CA 90045.

Date Revoked: November 26, 1991.

Reason: Surrendered license voluntarily.

Bryant L. VanBrakle,

Director, Bureau of Tariffs, Certification and Licensing.

[FR Doc. 92-73 Filed 1-2-92; 8:45 am]

BILLING CODE 6730-01-M

FEDERAL RESERVE SYSTEM

MASSBANK Corp., et al.; Formations of; Acquisitions by; and Mergers of Bank Holding Companies

The companies listed in this notice have applied for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) and § 225.14 of the Board's Regulation Y (12 CFR 225.14) to become a bank holding company or to acquire a bank or bank holding company. The factors that are considered in acting on the applications are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Unless otherwise noted, comments regarding each of these applications must be received not later than January 27, 1992.

A. Federal Reserve Bank of Boston (Robert M. Brady, Vice President) 600 Atlantic Avenue, Boston, Massachusetts 02106:

1. *MASSBANK Corp.*, Reading, Massachusetts; to become a bank holding company by acquiring 100 percent of the voting shares of MASSBANK for Savings, Reading, Massachusetts.

B. Federal Reserve Bank of Cleveland (John J. Wixted, Jr., Vice President) 1455 East Sixth Street, Cleveland, Ohio 44101:

1. *Majoning National Bancorp, Inc.*, Youngstown, Ohio; to become a bank holding company by acquiring 100 percent of the voting shares of The Mahoning National Bank of Youngstown, Youngstown, Ohio.

C. Federal Reserve Bank of Richmond (Lloyd W. Bostian, Jr., Vice President) 701 East Byrd Street, Richmond, Virginia 23261:

1. *Triangle Bancorp, Inc.*, Raleigh, North Carolina; to become a bank holding company by acquiring 100 percent of the voting shares of Triangle Bank and Trust Company, Raleigh, North Carolina.

D. Federal Reserve Bank of San Francisco (Kenneth R. Binning, Director, Bank Holding Company and International Regulation) 101 Market Street, San Francisco, California 94105:

1. *Continental Bancorporation*, Las Vegas, Nevada; to become a bank holding company by acquiring 100 percent of the voting shares of Continental National Bank, Las Vegas, Nevada.

Board of Governors of the Federal Reserve System, December 27, 1991.

Jennifer J. Johnson,

Associate Secretary of the Board.

[FR Doc. 92-44 Filed 1-2-92; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Health Care Policy and Research

Meeting of the National Advisory Council for Health Care Policy, Research, and Evaluation

AGENCY: Agency for Health Care Policy and Research.

ACTION: Notice of public meeting.

SUMMARY: In accordance with section 10(a) of the Federal Advisory Committee Act, this notice announces a meeting of the National Advisory Council for Health Care Policy, Research, and Evaluation.

DATES: The meeting will be open to the public on Wednesday, January 22, 1992, from 9 a.m. to 5 p.m.

In accordance with the provisions set forth in section 552b(c)(6), title 5, U.S. Code, and section 10(d) of the Federal Advisory Committee Act, a meeting closed to the public will be held on January 23, 1992, from 8:30 a.m. to 12:30 p.m. to review, discuss, and evaluate grant applications. The discussion and review of grant applications could reveal confidential personal information, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

ADDRESS: The meeting will be at the Hyatt Regency Hotel, 7400 Wisconsin Avenue, Bethesda, Maryland 20814.

FOR FURTHER INFORMATION CONTACT: Judith D. Moore, Executive Secretary at (301) 227-8142.

SUPPLEMENTARY INFORMATION:

I. Purpose

Section 921 of the Public Health Service Act (42 U.S.C. 299c) establishes the National Advisory Council for Health Care Policy, Research, and Evaluation. The Council provides advice to the Secretary and the Administrator, Agency for Health Care Policy and Research (AHCPR), on matters related to the actions of AHCPR to enhance the quality, appropriateness, and effectiveness of health care services and access to such services through scientific research and the promotion of improvements in clinical practice and the organization, financing, and delivery of health care services.

The Council is composed of public members appointed by the Secretary. These members are:

Linda H. Aiken, Ph.D.; Mr. Edward C. Bessey; Joseph F. Boyle, M.D.; Linda Burnes-Bolton, Dr. P.H.; Joseph T. Curti, M.D.; Gary L. Filerman, Ph.D.; Juanita W. Fleming, Ph.D.; David Hayes-Bautista, Ph.D.; William S. Kiser, M.D.; Kermit B. Knudsen, M.D.; Norma M. Lang, Ph.D.; Barbara J. McNeil, M.D.; Mr. Walter J. McNerney; Lawrence H. Meskin, D.D.S., Ph.D.; Theodore J. Phillips, M.D.; Barbara Starfield, M.D.; and Donald E. Wilson, M.D.

There also are Federal ex officio members. These members are:

Administrator, Alcohol, Drug Abuse and Mental Health Administration; Director, National Institutes of Health; Director, Centers for Disease Control; Administrator, Health Care Financing Administration; Commissioner, Food and Drug Administration; Assistant Secretary of Defense (Health Affairs);

and Chief Medical Director, Department of Veterans Affairs.

II. Agenda

On Wednesday, January 22, 1992, the open portion of the meeting will begin at 9 a.m. with the call to order by the Council Acting Chairman. The Administrator will report on AHCPR activities and discuss the Council's advice on AHCPR planning activities. In the afternoon the AHCPR Administrator and other AHCPR staff will present an update on AHCPR's clinical guidelines development followed by a presentation by AHCPR staff on grant review procedures. The Council will recess at 5 p.m.

On Thursday, January 23, 1992, the Council will resume at 8:30 a.m. with a closed meeting to review grant applications. The meeting will then adjourn at 12:30 p.m.

Agenda items are subject to change as priorities dictate.

Dated: December 19, 1991.

J. Jarrett Clinton,
Administrator.

[FR Doc. 92-6 Filed 1-2-92; 8:45 am]

BILLING CODE 4160-90-M

Food and Drug Administration

[Docket No. 91F-0480]

E.I. Dupont de Nemours and Co., Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that E.I. duPont de Nemours and Co., Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of 1,1-difluoroethane as a blowing agent in the production of polystyrene articles intended to contact food.

FOR FURTHER INFORMATION CONTACT: Daniel N. Harrison, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 2B4303) has been filed by E.I. duPont de Nemours and Co., Inc., Wilmington, DE 19898. The petition proposes to amend the food additive regulations to provide for the safe use of 1,1-difluoroethane as a blowing agent in the production of

polystyrene articles intended to contact food.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: December 23, 1991.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 92-53 Filed 1-2-92; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 91F-0465]

Gycor International, Ltd.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Gycor International, Ltd., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of citric acid, disodium ethylenediamine tetraacetate, sodium lauryl sulfate, and monosodium phosphate as components of a sanitizing solution for general use on food-contact surfaces.

FOR FURTHER INFORMATION CONTACT: Mitchell Cheeseman, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 2B4301) has been filed by Gycor International, Ltd., c/o Hogan & Hartson, 555 Thirteenth St. NW., Washington, DC 20004. The petition proposes to amend the food additive regulations in § 178.1010 *Sanitizing solutions* (21 CFR 178.1010) to provide for the safe use of citric acid, disodium ethylenediamine tetraacetate, sodium lauryl sulfate, and monosodium phosphate as components of a sanitizing solution intended for general use on food-contact surfaces.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the

notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: December 23, 1991.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 92-52 Filed 1-2-92; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 91F-0399]

3-V Chemical Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that 3-V Chemical Corp. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of 1,3-propanediamine, N,N"-1,2-ethanediybis-, polymer with N-butyl-2,2,6,6-tetramethyl-4-piperidinamine and 2,4,6-trichloro-1,3,5-triazine as a light stabilizer for polypropylene and polyethylene complying with 21 CFR 177.1520.

FOR FURTHER INFORMATION CONTACT: Julius Smith, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 1B4277) has been filed by 3-V Chemical Corp., P.O. Drawer Y, Georgetown, SC 29442. The petition proposes to amend the food additive regulations in § 178.2010 Antioxidants and/or stabilizers for polymers (21 CFR 178.2010) to provide for the safe use of 1,3-propanediamine, N,N"-1,2-ethanediybis-, polymer with N-butyl-2,2,6,6-tetramethyl-4-piperidinamine and 2,4,6-trichloro-1,3,5-triazine as a light stabilizer for polypropylene and polyethylene complying with 21 CFR 177.1520.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the

Federal Register in accordance with 21 CFR 25.40(c).

Dated: December 23, 1991.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 92-54 Filed 1-2-92; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 91M-0493]

Staar Surgical Co.; Premarket Approval of Elastimide™ Models AQ-1000, AQ-1001, AQ-1002, AQ-1005, and AQ-1016 Silicone Posterior Chamber Intraocular Lenses

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application by Staar Surgical Co., Monrovia, CA, for premarket approval, under section 515 of the Federal Food, Drug, and Cosmetic Act (the act), of the Elastimide™ Models AQ-1000, AQ-1001, AQ-1002, AQ-1005, and AQ-1016 Silicone Posterior Chamber Intraocular Lenses. The devices are to be manufactured under an agreement with Softlensco, Inc., Los Angeles, CA, which has authorized Staar Surgical Co. to incorporate information contained in its approved premarket approval application (PMA) (P900048) for the Elastimide™ Models AQ-1000, AQ-1001, AQ-1002, AQ-1005, and AQ-1016 Silicone Posterior Chamber Intraocular Lenses. FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of November 29, 1991, of the approval of the application.

DATES: Petitions for administrative review by February 3, 1992.

ADDRESSES: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Donna L. Rogers, Center for Devices and Radiological Health (HFZ-463), Food and Drug Administration, 1390 Piccard Dr., Rockville, MD 20850, 301-427-1212.

SUPPLEMENTARY INFORMATION: On September 30, 1991, Staar Surgical Co., Monrovia, CA 91016, submitted to CDRH an application for premarket approval of Elastimide™ Models AQ-1000, AQ-1001, AQ-1002, AQ-1005, and AQ-1016 Silicone Posterior Chamber

Intraocular Lenses. These devices are indicated for primary implantation for the visual correction of aphakia in persons 60 years of age or older in whom a cataractous lens has been removed by extracapsular cataract extraction. The devices are intended to be placed in the ciliary sulcus or capsular bag. The application includes authorization from Softlensco, Inc., Los Angeles, CA 90071, to incorporate information contained in its approved PMA for Elastimide™ Models AQ-1000, AQ-1001, AQ-1002, AQ-1005, and AQ-1016 Silicone Posterior Chamber Intraocular Lenses.

In accordance with the provisions of section 515(f)(2) of the act as amended by the Safe Medical Devices Act of 1990, this PMA was not referred to the Ophthalmic Devices Panel, the FDA advisory panel, for review and recommendation because the information in the PMA substantially duplicates information previously reviewed by this panel. On November 29, 1991, CDRH approved the application by a letter to the applicant from the Director of the Office of Device Evaluation, CDRH.

A summary of the safety and effectiveness data on which CDRH based its approval is on file in the Dockets Management Branch (address above) and is available from that office upon written request. Requests should be identified with the name of the device and the docket number found in brackets in the heading of this document.

Opportunity for Administrative Review

Section 515(d)(3) of the act (21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, under section 515(g) of the act (21 U.S.C. 360e(g)), for administrative review of CDRH's decision to approve this application. A petitioner may request either a formal hearing under part 12 (21 CFR part 12) of FDA's administrative practices and procedures regulations for a review of the application and CDRH's action by an independent advisory committee of experts. A petition is to be in the form of a petition for reconsideration under § 10.33(b) (21 CFR 10.33(b)). A petitioner shall identify the form of review requested (hearing or independent advisory committee) and shall submit with the petition supporting data and information showing that there is a genuine and substantial issue of material fact for resolution through administrative review. After reviewing the petition, FDA will decide whether to grant or deny the petition and will publish a notice of its decision in the Federal Register. If FDA grants the

petition, the notice will state the issue to be reviewed, the form of review to be used, the persons who may participate in the review, the time and place where the review will occur, and other details.

Petitioners may, at any time on or before February 3, 1992, file with the Dockets Management Branch (address above) two copies of each petition and supporting data and information, identified with the name of the device and the docket number found in brackets in the heading of this document. Received petitions may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

This notice is issued under Federal Food, Drug, and Cosmetic Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Director, Center for Devices and Radiological Health (21 CFR 5.53).

Dated: December 24, 1991.

Elizabeth D. Jacobson,

Deputy Director, Center for Diseases and Radiological Health.

[FR Doc. 92-102 Filed 1-2-92; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 91M-0496]

Staar Surgical Co.; Premarket Approval of Elastic™ Model AA-4203 Silicone Posterior Chamber Intraocular Lens

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application by Staar Surgical Co., Monrovia, CA, for premarket approval, under section 515 of the Federal Food, Drug, and Cosmetic Act (the act), of the Elastic™ Model AA-4203 Silicone Posterior Chamber Intraocular Lens. The device is to be manufactured under an agreement with Softlensco, Inc., Los Angeles, CA, which has authorized Staar Surgical Co. to incorporate information contained in its approved premarket approval application (P880091) for the Elastic™ Model AA-4203 Silicone Posterior Chamber Lens. FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of November 29, 1991, of the approval of the application.

DATES: Petitions for administrative review by February 3, 1992.

ADDRESSES: Written requests for copies of the summary of safety and effectiveness data and petitions for